Skip to content

Neurocrine Biosciences

US · NBIX #1162 by market cap Listed 1970
143.47 -2.04 -1.40%
Live - 5344 symbols - heartbeat 444s ago · 2026-10-08 07:09
Pre-market 144.49 +0.71%
After-hours 143.47 0.00%
Overnight 143.47 0.00%
Market cap
14.58B
P/B
3.95
EPS
4.67
Reader sentiment Are you bullish or bearish on NBIX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
    TipRanks · 2026/8/7
  • Rating change
    J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $217
    Market Newswire · 2026/8/7
  • Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $183
    Market Newswire · 2026/9/11
  • Rating change
    Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $218
    Market Newswire · 2026/8/13
  • Rating change
    Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $253
    Market Newswire · 2026/9/3
  • Rating change
    Deutsche Bank Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $165
    Market Newswire · 2026/8/13
  • UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $214
    Market Newswire · 2026/9/29
  • Rating change
    A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $196 to $225
    Market Newswire · 2026/7/31
  • Rating change
    A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $194 to $249
    Market Newswire · 2026/8/4
  • Rating change
    A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $190 to $249
    Market Newswire · 2026/8/1
  • Rating change
    BMO Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $190
    Market Newswire · 2026/8/18
  • Rating change
    CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $210
    Market Newswire · 2026/8/3
  • Rating change
    Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $249
    Market Newswire · 2026/8/3
  • RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $198
    Market Newswire · 2026/9/15
  • Rating change
    Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $215
    Market Newswire · 2026/8/17
  • Rating change
    Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $182
    Market Newswire · 2026/8/25
  • Neurocrine (NBIX) Receives a Buy From CCB Intl.
    TipRanks · 2026/9/21
  • Rating change
    Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Cuts Target Price to $182
    Market Newswire · 2026/8/13
  • Rating change
    Citi Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $253
    Market Newswire · 2026/9/4
  • Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $218
    Market Newswire · 2026/9/26

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:09:44 · For reference only, not investment advice and not tailored to your situation.